Asia
One year after snagging $310 million in a financing round, LianBio raised $325M in its initial public offering. Its stock begins selling today on Nasdaq under the ticker symbol “LIAN.”
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
Daiichi Sankyo announced the decision in its third quarter financial report this morning, where it said that the Phase I data yielded no clear responses in GIST patients.
Yet another busy week for clinical trial news. Here’s a look.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.
10X Genomics is continuing to increase its presence outside of the United States, this time with its first manufacturing facility outside of the country.
Scientists are scrambling to find the cause for the sudden spike in human cases of avian influenza A (H5N6) in China to 21 this year, from only five in 2020.
C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located.
PRESS RELEASES